Overview

Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-02-01

Target enrollment:

Participant gender:

Summary

The aim of the study is to evaluate the efficacy and safety of netakimab compared with placebo in a pediatric population of subjects over 6 years of age with moderate to severe plaque psoriasis. The study will have randomized, double-blind, placebo-controlled study with open-arm comparison.

Phase:

PHASE3

Details

Lead Sponsor:

Biocad

Treatments:

Adalimumab
netakimab